TNF Inhibitor denied for missing prior authorization by Florida Blue?

Florida Blue uses Prime Therapeutics or CVS Caremark depending on plan line. Step therapy through preferred biosimilar.

FL Statute 627.42393 limits step therapy when prior failure documented. Demand peer-to-peer review. Cite continuity-of-care for stable patients.

## Why Florida Blue Requires Prior Authorization for TNF Inhibitors

TNF inhibitors are high-cost specialty biologics used to treat immune-mediated inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and moderate-to-severe plaque psoriasis. Florida Blue, like virtually all major insurers, requires prior authorization (PA) for this drug class before dispensing is covered. A denial for "prior authorization required" usually means either that no PA was requested before the prescription was filled, or that a PA was submitted but deemed incomplete.

## Why This Denial Is Often Appealable

If a PA was never filed, your prescriber can submit one retroactively in many situations, and Florida Blue may process it as a coverage determination rather than a straight denial. If a PA was filed and denied, you have the right to a full internal appeal and, if that fails, binding external review. Incomplete submissions are particularly common — gathering the right documentation on appeal frequently reverses these decisions.

## Your Federal Appeal Rights

• Internal appeal: File a written appeal within the deadline shown on your denial notice (commonly 180 days). Florida Blue must decide pre-service appeals within 30 days for non-urgent requests; post-service appeals within 60 days.
• External review (ACA §2719): If the internal appeal is denied, request independent external review through an IRO within approximately four months of the final denial. The IRO's decision is binding on Florida Blue.
• Expedited review: If delay risks serious harm, request expedited review; decisions are typically issued within 72 hours.
• ERISA §503: Employer-sponsored plan members are entitled to a full-and-fair review with access to all documents used in the coverage decision.

## Documentation to Gather

1. Confirmed diagnosis with ICD code — physician notes that clearly document the condition for which the TNF inhibitor is prescribed. 2. Prior-treatment history — a dated record of every previously tried therapy (drug name, start/stop dates, reason for discontinuation), demonstrating the step-therapy sequence already completed. 3. Clinical severity documentation — objective chart findings (disease-activity scores, lab markers, imaging) showing the condition's impact and why standard therapies were insufficient. 4. Prescriber medical-necessity letter — a letter from the treating specialist that explicitly maps the patient's clinical profile to each criterion listed in Florida Blue's PA criteria for this drug class. 5. Florida Blue's current PA criteria — download the most recent version of their medical policy for TNF inhibitors from floridablue.com so your appeal can address every stated requirement.

## Criteria-Mapping Strategy

Obtain Florida Blue's published PA criteria for TNF inhibitors and place each requirement in a two-column table. In the right column, provide the exact chart entry, lab value, or date that satisfies it. Where the criteria reference the FDA-approved prescribing label (for dosing or indication), attach the relevant pages of the label. This structured format converts your appeal from a narrative into a compliance checklist, making it difficult for the reviewer to claim any element was missing.